Document is current
Any future updates will be listed below
-
Authors
Wendt, Frank R. https://orcid.org/0000-0002-2108-6822
Pathak, Gita A.
Deak, Joseph D.
De Angelis, Flavio
Koller, Dora https://orcid.org/0000-0002-0415-0466
Cabrera-Mendoza, Brenda
Lebovitch, Dannielle S.
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Koenen, Karestan C.
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Huckins, Laura M. https://orcid.org/0000-0002-5369-6502
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (F32 MH122058)
Beatrice and Samuel A. Seaver Foundation (Faculty Scholar Award)
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (R21 DC018098)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R33 DA047527)
- License Information
-
More Information
Article History
Received: 26 August 2021
Revised: 18 January 2022
Accepted: 2 February 2022
First Online: 18 February 2022
Competing interests
: HRK is a member of an advisory board for Dicerna Pharmaceuticals, a consultant to Sophrosyne Pharmaceuticals, a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which for the past 3 years was supported by AbbVie, Alkermes, Amygdala Neurosciences, Arbor, DIicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer, and is paid for his editorial work on the journal <i>Alcoholism: Clinical and Experimental Research</i>. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. MBS is paid for his editorial work on the journals <i>Biological Psychiatry</i> and <i>Depression and Anxiety</i>, and the health professional reference Up-To-Date; he has also in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech, and has stock options in Oxeia Biopharmaceuticals and Epivario. RP and JG are paid for their editorial work on the journal <i>Complex Psychiatry</i>. The other authors have no competing interests to report.
